Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037128
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2002-05-16
Brief Title:
Study of GL701 in Men With Systemic Lupus Erythematosus
Sponsor:
Genelabs Technologies
Organization:
Genelabs Technologies
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2004-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lupus flares and other symptoms associated with systemic lupus erythematosus SLE may be caused by a deficiency of dehydroepiandrosterone DHEA GL701 is an investigational new drug meant to enhance DHEA levels This study is designed to evaluate both the safety and efficacy of GL701 in male lupus patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None